<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922699</url>
  </required_header>
  <id_info>
    <org_study_id>DRL _ RUS / PMS / 201 2 / OMEZ</org_study_id>
    <nct_id>NCT02922699</nct_id>
  </id_info>
  <brief_title>Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases</brief_title>
  <acronym>Omez-RU2013</acronym>
  <official_title>A Prospective, Randomized, Open-label Comparative Study to Evaluate the Efficacy and Safety of Two First-line H.Pylori Eradication Regimens Including the Omeprazole 40 or 80 mg, Clarithromycin and Amoxicillin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of efficacy of H.pylori eradication during first line therapy using standard or&#xD;
      high doses of omeprazole administered twice daily in combination with amoxicillin and&#xD;
      clarithromycin for 10 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale for the use of high doses of omeprozo la - 80 mg in the scheme of eradication&#xD;
      therapy 1st line Intensive study of the microorganism Helicobacter pylori (H. pylori) Prodo l&#xD;
      zhaetsya more than 30 years. Actively study the role of infection in the development and&#xD;
      maintenance of chronic inflammation of the digestive system and especially its capabilities&#xD;
      and elimin tion. In 1997, the first recommendations concerning diagnosis and were developed n&#xD;
      infection, Helicobacter therapy indications for various embodiments and treatment of diseases&#xD;
      associated with H. pylori. These guidelines are called &quot;first the Maastricht Treaty&quot;, or&#xD;
      Maastricht-1 - the main document Regla and tail by the tactics of patients with H.&#xD;
      pylori-associated ill and tions. In the future, in connection with obtaining new data on the&#xD;
      properties of the causative agent, spreading disease, which occurs in H. pylori plays a&#xD;
      pathogen is, genetically role, and the appearance of information on the effectiveness of&#xD;
      different eras schemes and dikatsionnoy therapy recommendations were renegotiated, received&#xD;
      sootvets t tively name Maastricht 2 (2000), and Maastricht-3 (2005). As antihelikoba to puter&#xD;
      first line therapy authors agreement offer a combination of a proton pump inhibitor (or&#xD;
      ranitidine bismuth citrate) in the standard dosage (OMe n Rasoli 20mg Lansoprazole 30 mg&#xD;
      Pantoprazole 40 mg Rabeprazole 20 mg esomeprazole 20 mg) twice a day, in combination with&#xD;
      clarithromycin (R) 500 mg twice daily and amoxicillin (a) 1000 mg twice a day or&#xD;
      metronidazole (M) 500 mg twice a day for at least 7 days.&#xD;
&#xD;
      Under the conditions commonly konstatiruemogo progressive growth of a microorganism&#xD;
      resistance to most commonly used antibiotics, that it and nuemo reduces the efficiency of&#xD;
      eradication (data along with 80-90% to 30-60% and even up to 12,5-18,3%) dictated the&#xD;
      development of new recommendations for Dr. s processing of highly efficient schemes of&#xD;
      eradication therapy [1, 2].&#xD;
&#xD;
      The recommendations of the last convocation of experts presented at the XXIV International&#xD;
      with e nar on the role of Helicobacter and related bacteria in the development of chronic e&#xD;
      tion of inflammation of the digestive tract and stomach cancer (Symposium &quot;Maastricht-4&quot; on&#xD;
      13 September 2011, Dublin, Ireland) [3] .&#xD;
&#xD;
      The methods of increasing the effectiveness of eradication therapy, according to this claim&#xD;
      about the recent agreement includes the use of high (4-fold) doses of PPI, SW e crease the&#xD;
      duration of therapy to 10-14 days (increases the effectiveness of treatment at 5%), the use&#xD;
      of probiotics and prebiotics as adjuvant therapy [3, 4, 5,6].&#xD;
&#xD;
      Increasing doses of PPIs increases the concentration of drug in the blood, and consequently s&#xD;
      but increases the antisecretory effect. When using high doses of drugs of this group in the&#xD;
      eradication schemes, serious side effects have not time in h penetrate due to a short course&#xD;
      of taking the drugs [7].&#xD;
&#xD;
      The present study is designed to investigate the efficacy and bezop with of high doses of&#xD;
      PPIs in the schemes of eradication in terms of Maximal s tion efficiency of therapy of H.&#xD;
      pylori.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H Pylori eradicaion rates</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Omeprazole 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omez 40mg OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omez 80mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMEZ 40</intervention_name>
    <description>Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin</description>
    <arm_group_label>Omeprazole 40mg</arm_group_label>
    <other_name>OMEPRAZOLE 40MG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMEZ 80</intervention_name>
    <description>Omez 80 patients for 58days along with Amoxicilin and Clarithromycin</description>
    <arm_group_label>Omeprazole 80 mg</arm_group_label>
    <other_name>OMEPRAZOLE 80 MG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes between the ages of 18 and 75 years old, ready to sign informed&#xD;
             consent and and agree to follow all requirements of study protocol.&#xD;
&#xD;
          -  The patient should be prepared to fill out questionnaires on their own wedge and&#xD;
             symptoms.&#xD;
&#xD;
          -  Non pregnant, not nursing patient.&#xD;
&#xD;
          -  Patients must be either n of stklimaktericheskom period, or surgically sterile, or&#xD;
             throughout the study period using contraceptive methods, the reliability of more than&#xD;
             90%. - Contraceptive methods with the reliability of more than 90% of the normal used&#xD;
             e of include the cervical cap with spermicide, diaphragm with spermicide, condoms,&#xD;
             oral contraceptives, intrauterine devices, acetate HCWs to siprogesterona and&#xD;
             levonorgestrel subdermal implants;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of surgery performed to reduce gastric acid secretion in the stomach or&#xD;
             esophagus to operations and / or upper digestive tract.&#xD;
&#xD;
          -  The presence of obstructive strictures or esophageal ulcers, varicose veins vehi ie&#xD;
             water, esophageal achalasia.&#xD;
&#xD;
          -  Barrett's esophagus.&#xD;
&#xD;
          -  patients taking other medications for GERD over a period of two weeks or PPIs during&#xD;
             the preceding and a following of the month.&#xD;
&#xD;
          -  Zollinger-Ellison syndrome .&#xD;
&#xD;
          -  Peptic ulcer and 12 duodenal ulcer in acute&#xD;
&#xD;
          -  erosive gastro.&#xD;
&#xD;
          -  Cancer of the stomach or esophagus.&#xD;
&#xD;
          -  Coronary heart disease.&#xD;
&#xD;
          -  Colic disease.&#xD;
&#xD;
          -  Chronic pancreatitis.&#xD;
&#xD;
          -  Gallstone disease.&#xD;
&#xD;
          -  Pyloric stenosis.&#xD;
&#xD;
          -  Regular intake of steroids or any other drugs ulcerogenic, n as an example of NSAIDs.&#xD;
&#xD;
          -  Pregnancy, Kor m tion feeding.&#xD;
&#xD;
          -  Patients with esophagitis endoscopically established 4 th or higher degree in s&#xD;
             reflection (on a modified scale Hetzel-Dent ) .&#xD;
&#xD;
          -  Impaired function of average weight of the liver.&#xD;
&#xD;
          -  hypersensitivity to the drug: omeprazole and domperidone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V.D Pasechnikov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stavropol State Medical University1</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

